PharmaCyte Biotech (PMCB) Free Cash Flow (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Free Cash Flow of -$1.4 million for Q2 2026, down 33.85% year-over-year from -$2.1 million in Q2 2025, and down 76.98% quarter-over-quarter from -$786848.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Free Cash Flow (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Free Cash Flow for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Free Cash Flow fell 33.85% year-over-year to -$1.4 million; the TTM figure through Apr 2026 stood at -$5.2 million (down 73.02% YoY), while the FY2026 annual figure was -$5.2 million, down 73.02% from the prior year.
- Free Cash Flow slipped to -$1.4 million in Q2 2026 per PMCB's latest filing, from -$786848.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $342959.0 in Q3 2023 and bottomed at -$2.0 million in Q3 2025.
- Historically, Free Cash Flow has averaged -$864826.8 across 5 years, with a median of -$883185.5 in 2025.
- Annual changes were most pronounced in 2023 — Free Cash Flow surged 131.63% — and 2025, when it slumped 434.15%.
- PharmaCyte Biotech's Free Cash Flow stood at -$1.9 million in 2022, then decreased by 5.59% to -$2.0 million in 2023, then surged by 46.85% to -$1.1 million in 2024, then grew by 7.13% to -$979523.0 in 2025, then plunged by 42.17% to -$1.4 million in 2026.
- Business Quant data shows PMCB's Free Cash Flow at -$1.4 million in Q2 2026, -$786848.0 in Q1 2026, and -$979523.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -1.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.39 Mn |
| Apr 30, 2026 | -1.39 Mn |
| Jan 31, 2026 | -786,848.00 |
| Jan 31, 2026 | -786,848.00 |
| Oct 31, 2025 | -979,523.00 |
| Oct 31, 2025 | -979,523.00 |
| Jul 31, 2025 | -1.99 Mn |
| Jul 31, 2025 | -1.99 Mn |
| Apr 30, 2025 | -1.04 Mn |
| Apr 30, 2025 | -1.04 Mn |
| Jan 31, 2025 | -509,893.00 |
| Jan 31, 2025 | -509,893.00 |
| Oct 31, 2024 | -1.05 Mn |
| Oct 31, 2024 | -1.05 Mn |
| Jul 31, 2024 | -373,297.00 |
| Jul 31, 2024 | -373,297.00 |
| Apr 30, 2024 | -332,958.00 |
| Apr 30, 2024 | -332,958.00 |
| Jan 31, 2024 | -177,104.00 |
| Jan 31, 2024 | -177,104.00 |